IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
📊 Approval movers
Jensen Huang
100%
Nanobiotix Reports 79% Locoregional Control in Recurrent Lung Cancer Trial
Nanobiotix
— Sep 14, 2026
Nanobiotix's updated Phase 1 data for JNJ-1900 (NBTXR3) in inoperable, locoregionally recurrent NSCLC show no dose-limiting toxicities and a feasible intratumoral injection, with one-year results of 79% locoregional control, 61% LPFS, and 70% OS achieved at a lower re-irradiation dose. The findings reinforce the hafnium oxide nanoparticle–based radiosensitizer's potential to enable safe retreatment and spur further enrollment in dose-escalation and expansion cohorts.
+3
0
2
Share
Sam Okafor
The fact that it works with lower re-irradiation doses could mean fewer side effects for patients facing this again.
Companies Plan Presentations at H.C. Wainwright Conference
Business
— Sep 8, 2026
Multiple biotech and mining firms announced participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York this fall, with senior executives set to present or engage in investor meetings to raise visibility. Included are Assembly Biosciences, Nanobiotix, Artelo Biosciences, Fortress Biotech, and U.S. Gold Corp, each outlining presentations or project highlights and strategic discussions.
+2
0
Share